Sientra Inc (NASDAQ:SIEN) – Dougherty & Co issued their Q1 2019 earnings estimates for shares of Sientra in a research note issued on Wednesday, March 13th. Dougherty & Co analyst K. Bauser expects that the medical instruments supplier will post earnings of ($0.81) per share for the quarter. Dougherty & Co currently has a “Buy” rating and a $27.00 target price on the stock. Dougherty & Co also issued estimates for Sientra’s FY2019 earnings at ($2.98) EPS and FY2020 earnings at ($2.32) EPS.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.19). Sientra had a negative net margin of 121.28% and a negative return on equity of 123.50%. The firm had revenue of $19.02 million during the quarter, compared to analysts’ expectations of $18.87 million.
Shares of NASDAQ SIEN opened at $8.84 on Friday. Sientra has a 1 year low of $7.74 and a 1 year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77. The stock has a market cap of $325.46 million, a P/E ratio of -2.72 and a beta of -0.04.
Large investors have recently bought and sold shares of the stock. Alliancebernstein L.P. boosted its stake in Sientra by 18.8% during the third quarter. Alliancebernstein L.P. now owns 21,500 shares of the medical instruments supplier’s stock worth $513,000 after acquiring an additional 3,400 shares in the last quarter. Federated Investors Inc. PA boosted its stake in Sientra by 19,162.9% during the third quarter. Federated Investors Inc. PA now owns 66,457 shares of the medical instruments supplier’s stock worth $1,587,000 after acquiring an additional 66,112 shares in the last quarter. Northern Trust Corp boosted its stake in Sientra by 74.2% during the second quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock worth $5,278,000 after acquiring an additional 115,283 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Sientra during the third quarter worth about $3,767,000. Finally, AQR Capital Management LLC boosted its stake in Sientra by 41.5% during the third quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock worth $462,000 after acquiring an additional 5,675 shares in the last quarter. 92.79% of the stock is currently owned by institutional investors and hedge funds.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: What are gap-down stocks?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.